Innovative Therapeutics Kojin Therapeutics is at the forefront of cell death and ferroptosis biology, developing first-in-class treatments for cancer, autoimmune, and inflammatory diseases. This positions the company as a unique partner for organizations seeking advanced biologics or specialized drug discovery solutions in niche therapeutic areas.

Growing Financial Capacity With recent funding of $60 million and annual revenues approaching $25 million, Kojin has significant resources to expand its R&D efforts and accelerate clinical development, making it an attractive collaborator for partners interested in innovative biotech investments or joint ventures.

Research-Driven Platform Kojin's integrated drug discovery platform leverages computational chemistry, structural biology, and mechanism-driven pharmacology, offering potential licensing or co-development opportunities for companies seeking cutting-edge technologies in precision medicine and cell death pathways.

Strategic Location & Leadership Based in Boston with a leadership team experienced in biotechnology entrepreneurship and clinical development, Kojin is well-positioned to engage with local biotech hubs, research institutions, and potential partners interested in collaborative innovation or regional drug development efforts.

Niche Market Focus Specializing in ferroptosis modulation for a range of disorders, Kojin targets a promising but specialized market segment. Companies with interests in cancer immunotherapy, autoimmune diseases, or inflammation could consider Kojin for strategic alliances or technology licensing to expand product pipelines.